Advantages and drawbacks of dexamethasone in glioblastoma multiforme

被引：24

作者：

Afshari, Amir R. ^{[1
]}

Sanati, Mehdi ^{[2
]}

Aminyavari, Samaneh ^{[3
]}

Shakeri, Farzaneh ^{[1
]}

Bibak, Bahram ^{[1
]}

Keshavarzi, Zakieh ^{[1
]}

Soukhtanloo, Mohammad ^{[4
]}

Jalili-Nik, Mohammad ^{[4
]}

Sadeghi, Mohammad Montazami ^{[1
]}

Mollazadeh, Hamid ^{[1
]}

Johnston, Thomas P. ^{[5
]}

Sahebkar, Amirhossein ^{[6
,7
,8
,9
]}

机构：

[1] North Khorasan Univ Med Sci, Fac Med, Dept Physiol & Pharmacol, Bojnurd, Iran

[2] Birjand Univ Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Birjand, Iran

[3] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Neurosci & Addict Studies, Tehran, Iran

[4] Mashhad Univ Med Sci, Fac Med, Dept Clin Biochem, Mashhad, Razavi Khorasan, Iran

[5] Univ Missouri, Sch Pharm, Div Pharmacol & Pharmaceut Sci, Kansas City, MO 64110 USA

[6] Mashhad Univ Med Sci, Biotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad, Razavi Khorasan, Iran

[7] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Razavi Khorasan, Iran

[8] Univ Western Australia, Sch Med, Perth, WA, Australia

[9] Mashhad Univ Med Sci, Sch Pharm, Dept Biotechnol, Mashhad, Razavi Khorasan, Iran

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 172卷

关键词：

Glioblastoma multiforme; Dexamethasone; Cerebral edema; Inflammation; Proliferation; NF-KAPPA-B; CELL LUNG-CANCER; GLUCOCORTICOID-INDUCED APOPTOSIS; LOW-DOSE DEXAMETHASONE; BRAIN TUMOR BARRIER; INDUCED CHEMOTHERAPY RESISTANCE; POTASSIUM CHANNEL EXPRESSION; ACUTE LYMPHOBLASTIC-LEUKEMIA; PROSTATE-CANCER; GROWTH-FACTOR;

D O I：

10.1016/j.critrevonc.2022.103625

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The most widespread, malignant, and deadliest type of glial tumor is glioblastoma multiforme (GBM). Despite radiation, chemotherapy, and radical surgery, the median survival of afflicted individuals is about 12 months. Unfortunately, existing therapeutic interventions are abysmal. Dexamethasone (Dex), a synthetic glucocorticoid, has been used for many years to treat brain edema and inflammation caused by GBM. Several investigations have recently shown that Dex also exerts antitumoral effects against GBM. On the other hand, more recent disputed findings have questioned the long-held dogma of Dex treatment for GBM. Unfortunately, steroids are associated with various undesirable side effects, including severe immunosuppression and metabolic changes like hyperglycemia, which may impair the survival of GBM patients. Current ideas and concerns about Dex's effects on GBM cerebral edema, cell proliferation, migration, and its clinical outcomes were investigated in this study.

引用

页数：19

共 318 条

[1] Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF--driven progression of pancreatic cancer [J].

Abukiwan, Alia ;

Nwaeburu, Clifford C. ;

Bauer, Nathalie ;

Zhao, Zhefu ;

Liu, Li ;

Gladkich, Jury ;

Gross, Wolfgang ;

Benner, Axel ;

Strobel, Oliver ;

Fellenberg, Joerg ;

Herr, Ingrid .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 54 (01) :53-64

[2] Glucocorticoids attenuate the sensitivity of glucocorticoid-resistant lymphoid cells to doxorubicin via reduction in OCTN2 [J].

Akaihata, Mitsuko ;

Shikama, Yayoi ;

Matsumoto, Yoshiyuki ;

Ono, Tomoyuki ;

Kimura, Junko ;

Hosoya, Mitsuaki .

MOLECULAR AND CELLULAR BIOCHEMISTRY, 2019, 459 (1-2) :49-59

[3] Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin-6 [J].

Akakura, K ;

Suzuki, H ;

Ueda, T ;

Komiya, A ;

Ichikawa, T ;

Igarashi, T ;

Ito, H .

PROSTATE, 2003, 56 (02) :106-109

[4] PKA-dependent growth stimulation of cells derived from human pulmonary adenocarcinoma and small airway epithelium by dexamethasone [J].

Al-Wadei, HAN ;

Takahasi, T ;

Schuller, HM .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (17) :2745-2753

[5] Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma [J].

Aldaz, Paula ;

Auzmendi-Iriarte, Jaione ;

Durantez, Maika ;

Lasheras-Otero, Irene ;

Carrasco-Garcia, Estefania ;

Zelaya, M. Victoria ;

Bragado, Laura ;

Olias-Arjona, Ana ;

Egana, Larraitz ;

Sampron, Nicolas ;

Morilla, Idoia ;

Redondo-Munoz, Marta ;

Rico, Mikel ;

Squatrito, Massimo ;

Maria-Alonso, Marta ;

Fernandez-Irigoyen, Joaquin ;

Santamaria, Enrique ;

Larrayoz, Inaki M. ;

Wellbrock, Claudia ;

Matheu, Ander ;

Arozarena, Imanol .

CANCERS, 2021, 13 (02) :1-23

[6]

AMANO Y, 1993, MOL PHARMACOL, V43, P176

[7] Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer [J].

Anderson, Tarah M. Regan ;

Ma, Shi Hong ;

Raj, Ganesh V. ;

Cidlowski, John A. ;

Helle, Taylor M. ;

Knutson, Todd P. ;

Krutilina, Raisa I. ;

Seagroves, Tiffany N. ;

Lange, Carol A. .

CANCER RESEARCH, 2016, 76 (06) :1653-1663

[8]

Arlt A, 2002, INT J CLIN PHARM TH, V40, P336

[9] Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group [J].

Arvold, Nils D. ;

Armstrong, Terri S. ;

Warren, Katherine E. ;

Chang, Susan M. ;

DeAngelis, Lisa M. ;

Blakeley, Jaishri ;

Chamberlain, Marc C. ;

Dunbar, Erin ;

Loong, Herbert H. ;

Macdonald, David R. ;

Reardon, David A. ;

Vogelbaum, Michael A. ;

Yuan, Ying ;

Weller, Michael ;

van den Bent, Martin ;

Wen, Patrick Y. .

NEURO-ONCOLOGY, 2018, 20 (07) :897-906

[10] Glucocorticoids in T cell development and function [J].

Ashwell, JD ;

Lu, FWM ;

Vacchio, MS .

ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :309-345

← 1 2 3 4 5 6 7 8 9 10 →